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Abstract
Background: Although vaccines are important in preventing viral infections by inducing neutralizing antibodies (nAbs), HIV-
1 has proven to be a difficult target and escapes humoral immunity through various mechanisms. We sought to test
whether HIV-1 Env mimics may serve as immunogens.
Methodology/Principal Findings: Using random peptide phage display libraries, we identified the epitopes recognized by
polyclonal antibodies of a rhesus monkey that had developed high-titer, broadly reactive nAbs after infection with a simian-
human immunodeficiency virus (SHIV) encoding env of a recently transmitted HIV-1 clade C (HIV-C). Phage peptide inserts
were analyzed for conformational and linear homology using computational analysis; some peptides mimicked various
domains of the original HIV-C Env, such as conformational V3 loop epitopes and the conserved linear region of the gp120 C-
terminus. Next, we devised a novel prime/boost strategy to test the immunogenicity of such phage-displayed peptides and
primed mice only once with HIV-C gp160 DNA followed by boosting with mixtures of recombinant phages.
Conclusions/Significance: This strategy, which was designed to focus the immune system on a few Env epitopes
(immunofocusing), not only induced HIV-C gp160 binding antibodies and cross-clade nAbs, but also linked a conserved HIV
Env region for the first time to the induction of nAbs: the C-terminus of gp120. The identification of conserved antigen
mimics may lead to novel immunogens capable of inducing broadly reactive nAbs.
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Introduction
HIV-1 continues to spread and has become a pandemic with
more than 34 million infected people and 14,000 new infections
per day [1]. Despite intense research efforts over the last 20 years,
a safe, effective vaccine against HIV-1/AIDS has not yet been
found, and its development remains a top priority. To date, large-
scale phase III clinical trials with candidate AIDS vaccines have
been disappointing (reviewed in [2,3]); such trials involved an
attempt to generate neutralizing antibody (nAb) response-based
vaccines based upon the surface subunit gp120 as well as a vaccine
strategy designed to induce cytotoxic T-lymphocyte (CTL)
responses with recombinant adenovirus vectors.
The viral envelope glycoproteins, non-covalently linked
trimers consisting of three gp120 and three gp41 subunits,
divert the immune system with variable loops which cover
neutralization-sensitive Env regions [4,5]. Env glycoproteins
frequently change their amino acid sequence in response to
selective pressure exerted by the immune system, thus presenting
the host with ever new antigens. Furthermore, the trimeric Env
structure shields important domains of the Env core, making
them inaccessible to antibody-mediated neutralization [6].
Conformational Env re-orientation upon CD4 receptor binding
transiently uncovers neutralization-sensitive regions for corecep-
tor binding until the viral envelope fuses with the host cell
membrane. Additionally, heavy glycosylation on the outside of
gp120 hides much of the protein core from antibody attack
(reviewed in [7,8]).
Proof-of-concept passive immunization studies in primates
challenged with simian-human immunodeficiency viruses
(SHIVs) yielded clear-cut evidence of the ability of several
neutralizing human monoclonal antibodies (nmAbs) to provide
complete protection from infection [9,10,11,12,13,14,15,16,17]
(reviewed in [18]). As a consequence, the epitopes targeted by
these nmAbs can be considered to be protective epitopes. The
nmAbs used in passive immunization experiments also neutral-
ized a number of primary strains of HIV-1 of different clades in
vitro alone and especially in combination in different assay
systems [19,20,21,22], indicating their broad reactivity. The
following nmAbs were involved in passive immunization studies
yielding complete protection: 2G12, which binds to mannose
residues on gp120 [23]; b12 or F105, antibodies against the CD4
binding site (CD4bs) [24,25]; as well as 4E10 and 2F5, which
bind to adjacent epitopes in the membrane proximal external
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three out of the four human nmAbs recognizing protective
epitopes to autoreactivity. These investigators demonstrated that
4E10 and to a somewhat lesser degree 2F5 cross-react with
cardiolipin, a self-antigen. This observation may explain the
inability to induce 4E10/2F5-like nAbs described by several
groups [28,29], since repeated boosting may eliminate autore-
active B cells. The protective epitopes may also be poorly
immunogenic because they either are located in recessed regions
of gp120 (the CD4bs) or are only transiently accessible (the
nmAbs targeting the extracellular domain of gp41). Further-
more, the special features of b12, including an unusually long,
finger-like structure, might prove to be difficult to induce with
current immunization strategies [30].
To identify promising vaccine candidates, it is important to
know which parts of HIV-1 Env are immunogenic and able to
induce protective antibodies in the host [31]. X-ray crystallogra-
phy has revealed important structural Env features and sites of
interaction with cellular receptors; it is becoming evident that
conserved Env parts are hidden from the immune system [8,32].
Thus far, however, this important information has not yet been
translated into a potent vaccine.
Valuable sources to study natural immune responses against
HIV-1 Env are sera with high-titer, cross-clade nAbs. The analysis
of such antibody responses might give important information
regarding structures on HIV-1 Envs that are conserved across
clades. We have identified a cohort of rhesus macaques infected
with SHIV-1157ip, a chimera that encodes env of a recently
transmitted HIV-C strain, or the related SHIV-1157ipd3N4 [33]
that developed high-titer nAb responses against homologous
SHIV-C as well as heterologous primary strains of HIV-1 of
different clades. We have employed phage display to identify the
HIV-C Env structures recognized by such broadly reactive sera.
Phage display [34] is a widely used technique to analyze
humoral immune responses [35,36,37,38,39,40,41], to map
antibody epitopes [42,43,44,45] or to study protein interaction
sites in general [46]. Until recently, the identification of
conformational epitopes was limited due to difficulties in
projecting the linear mimotope sequence onto a protein structure.
In the last years, attempts at closing this gap involved the
development of software [47,48,49,50,51,52] that allows three-
dimensional (3D) analysis. These programs project the linear
peptide sequence onto the 3D surface structure of target proteins
by using published protein structure files. 3DEX [52] maps
conformational mimotopes in 3D protein structures by using an
algorithm that takes into account the physicochemical neighbor-
hood of individual amino acids. A discontinuous epitope is
localized within the 3D protein structure by searching for a 3D fit
with partial amino acid strings of a given mimotope in a pre-set
distance on the protein surface. This algorithm is repeated for each
string of amino acids until the full peptide sequence is analyzed.
We dissected the humoral immune response of rhesus
monkeys with broadly reactive nAb responses using phage
display; recombinant phage peptide sequences were evaluated
for conformational and linear homologies to gp160 using
computational analysis [52]. Phage peptides encoding mimo-
topes were used to isolate the cognate antibodies from polyclonal
rhesus monkey serum; these affinity-purified antibodies were
then tested for differential ability to recognize native versus
denatured HIV-1 Env. Promising mimotopes were used in a
novel DNA prime/phage boost immunization strategy aimed at
focusing the antibody response on the regions represented by
mimotopes. This vaccination yielded cross-clade nabs responses
in immunized mice.
Results
Selection of HIV-C Env-Specific Mimotopes
We used polyclonal IgG from a rhesus monkey infected with
SHIV-1157ip, an R5 SHIV strain encoding env of a recently
transmitted Zambian HIV-C. This monkey (animal RKl-8) as well
as others of our cohort had developed high-titer, broadly reactive
nAbs that neutralized primary strains of HIV-1 and SHIV of
clades B and C (Table 1). High nAb titers were detected against
the early SHIV-C (SHIV-1157ip), the late isolate SHIV-
1157ipd3N4 [33], as well as against a heterologous R5 SHIV-C
generated in our group (SHIV-2873Nip). All sera were tested
against a panel of heterologous HIV clade C and B strains
(Table 1) and showed cross-clade nAbs against various strains,
including HIVpIndieC, HIVSF162.LS and HIVNL4-3, especially serum
of monkey RKl-8. Tissue culture supernatants of B-lymphocytic
cell lines generated from monkey RKl-8 showed neutralizing
activity against various SHIV and primary HIV strains,
including clades A, B and C (data not shown). Serum IgG was
immobilized on paramagnetic beads to isolate specific mimo-
topes by screening three different phage-displayed random
peptide libraries (7mer, cyclic 7mer, 12mer). For each screening,
94 single clones were tested in phage ELISA for their specificity
using SHIV-positive and SHIV-negative serum in parallel.
Positive clones were amplified and sequenced. Peptide insert
sequences were grouped according to their motifs and analyzed
for linear homology to parental gp160SHIV-1157ip. Using monkey
RKl-8 serum [33], we isolated 78 different clones; for gp120, we
identified mimotopes representing the V2 loop (9 clones), the V3
loop (21 clones) and the C-terminal domain (8 clones). Thirty-
four of the 78 clones resembled regions on gp41: The majority of
the clones represented a subdomain of the immunodominant
region (IDR), which is referred to as the immunodominant loop
[31] and contains the KLIC motif (20 clones); seven clones
shared homology with IDR outside the immunodominant loop
as well as several amino acid residues of the N-terminal heptad
repeat. Seven other clones showed homology to the MPER.
Finally, six phage inserts exhibited no apparent linear similarity
to gp160SHIV-1157ip.
Since several mimotopes displayed only minimal linear
homology to gp160SHIV-1157ip, we postulated that these exhibit
predominantly conformational homology. Using the above
mentioned software 3DEX [52] and a published gp120 structure
[53], we sought to identify conformational mimotopes. This
approach allowed us to identify an interesting V3 mimotope which
combines linear with structural homology (Figure 1, clone A12.2;
Figure 2). We compared the primary envelope sequence of the
structure file (PDB-ID: 2B4C; HIV-1 subtype B strain JR-FL) and
SHIV-1157ip. The amino acids in that stretch of V3 are almost
identical in sequence (inset Figure 2). 3DEX found two motifs: one
that comprises four amino acids at the crown of the V3 loop
(Figure 2, yellow/orange); and a second one that consists of
another four amino acids located near the crown (Figure 2, green).
Even though these eight amino acids are discontinuous, they are
found in neighboring locations at the Env surface.
Identification of a Conformational Mimotope of HIV-C
Env
To confirm that antibody binding to mimotope A12.2 involves
interaction with a conformational epitope and thus depends on the
structural integrity of the target HIV-C gp160, we compared
antibody binding to the region on HIV-1 Env represented by the
mimotope under native and reduced conditions. First, we used
affinity purification with immobilized recombinant phage to
HIV-C Mimotope Immuogens
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serum. The phage-affinity-purified antibodies were then subjected
to a dot spot analysis with homologous, trimeric gp160SHIV-1157ip
immobilized under native and denaturing conditions (Figure 3).
Binding of antibodies specific for clone A12.2 was abolished when
trimeric gp160 was denatured (Figure 3, field A1 and B1),
although specific binding was demonstrated to native Env. As
control, we used antibodies specific for a phage clone with greater
linear homology to the V3 loop (AIV12.4); as expected, these
antibodies recognized the native as well as the denatured forms of
gp160 (Figure 3, field A2 and B2). The control without spotted
gp160 (Figure 3, row C) showed no nonspecific antibody binding
on any strips. An additional positive control involved spotting anti-
monkey IgG (Figure 3, row D) and confirmed that equal amounts
of phage-affinity-purified antibodies had been applied to all strips.
Reactivity Profile of Mimotopes in the Context of Fusion
Proteins
To analyze if the HIV-1 Env mimotope motif groups represent
common antibody epitopes found in sera with broadly reactive
nAbs, we cloned selected mimotopes of all groups (except MPER)
into fusion proteins and tested the latter by ELISA and Western
blot analysis using a panel of rhesus monkey sera with broadly
neutralizing activity against different HIV-1 clades (Table 1). All
monkeys show broadly reactive nAbs against the homologous
SHIV-1157ip as well as against a heterologous HIV-1 clade C
(pIndieC) and clade B (HIVSF162.LS). In addition to screening with
serum from monkey RKl-8 described above, sera from monkeys
RAo-8, RJa-9 and RMf-9 were used for individual phage display
selections. The analysis revealed similar motif patterns to RKl-8,
including mimotopes representing immunodominant regions such
as V3 and KLIC, but we also selected new motifs representing
stretches of the Kennedy peptide [54] in gp41 and as yet
unidentified regions (data not shown).
To assess if the mimotopes in the context of a fusion protein
have conserved their structure, we performed ELISAs with sera
from RKl-8. All mimotope fusion proteins are recognized by
serum antibodies of RKl-8 (Figure 4, Figure 5A). Of note, there is
also binding to the conformational mimotope A12.2. The binding
pattern for RKl-8 was confirmed with sera taken at different time
points between 2003 and 2007 (data not shown). As summarized
in Figure 4, we extended the fusion protein ELISA and tested for
reactivity using individual serum samples from 11 rhesus monkeys
that included nine other monkeys with broadly reactive nAbs and
two naı ¨ve animals (Figure S1). As expected, we observed
comprehensive cross-reactivity of the KLIC mimotope with most
of the sera from our monkey cohort with high-level nAbs. Notably,
several rhesus monkey sera recognized selected V3 mimics,
especially the two mimotopes AIV3p12.5 and AIV12.4 (Figure 4,
Figure S1). Motifs isolated with serum from monkey RKl-8
representing the conserved C-terminus of gp120 and the IDR did
not react with sera from our rhesus monkey panel, although
reactivity was seen with autologous serum. Two naı ¨ve control sera
did not detect the fusion proteins and a control fusion protein
(pPeptide; empty backbone of fusion protein without mimotope
insert) was not detected by any of the rhesus monkey sera.
To confirm the ELISA results, we tested all rhesus monkey sera
for specific binding to the fusion proteins by Western blots. As an
example, we show the result for fusion protein AIV12.4, which was
broadly recognized by ELISA (Figure S1, Figure 5B). RKl-8 sera
from various time points detected this mimotope as well as several
other rhesus monkey sera from our panel. The naı ¨ve control sera
CF12 and RJi-2 did not bind to the mimotope fusion protein,
whereas the positive anti-His antibody control detected the fusion
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serum from the HIV1157i-infected human (1157MVP41m) and a
serum pool of HIV-C-infected individuals; both recognized the
mimotope (Figure 5B). Interestingly, the reactivity of RKl-8 serum
samples taken from different years with AIV12.4 varied as this
animal progressed to AIDS [33,55]. The early time point in 2004
showed a high reactivity with this linear mimotope in Western blot
and ELISA (Figure 5B, Figure S2). However, the samples taken at
later time points (2005 and 2007) showed a significant decrease in
antibody binding to this mimotope. As this animal eventually
progressed to AIDS, the antibody response to this protein epitope
on Env may have been compromised by the reduced numbers of
T-helper cells.
The ELISA and Western blot results show that the mimotopes
expressed in the context of a fusion protein conserved their
structure and were recognized by the monkey serum from which
they were selected as well as by other sera from our cohort.
Immunization Studies in Mice
To assess if the mimotopes representing different regions of HIV
Env are immunogenic, we performed a vaccine study in mice. We
used one DNA inoculation to prime the immune system with the
entire HIV-1 Env, followed by phage boosting to focus the
antibody response to a certain area of gp160.
We grouped recombinant phages according to their peptide
motifs and combined selected phages into five mixtures to
immunize mice (Figure 1). First, all mice received one priming
immunization with a DNA vector encoding gp160SHIV-1157ip; this
single DNA inoculation was previously shown to be insufficient for
induction of binding antibodies or nAbs [56]. After one DNA
prime, all mice were boosted four times with phage particles
(intervals of 4–5 weeks) (Figure 6) and their immune sera were
assessed for binding abs and nAbs.
First, we measured antibody binding titers for each group
against homologous gp160SHIV-1157ip by ELISA (Figure 7A) after
the four phage boosts. Mean titers ranged from 1:125 to 1:1362,
and almost all mice developed anti-Env titers. The lowest titer was
observed in the MPER group, the highest in the C-terminal
domain. However, antibody binding to HIV-1 gp160 does not
correlate with virus neutralization. Therefore, post-phage boost
sera (4
th bleed) were tested for neutralization of a heterologous
HIV-1 clade B strain, HIVSF162.LS; 59% of the animals had
measurable, cross-clade anti-HIV-1 nAbs (Figure 7B). The mean
IC50 in all groups ranged from 1:19 to 1:70. Of note, four out of
the six mice immunized with mimotopes representing the C-
terminal domain had nAbs, including two animals with IC50
values.1:100. To our knowledge, this is the first report of the C-
terminus of gp120 being linked to the induction of nAb responses.
Figure 1. Alignment of mimotopes selected with serum from monkey RKl-8 with the sequence of homologous gp160SHIV-1157ip.
Phage peptide sequences (clones) were grouped according to their motifs (V3, gp120 C-terminus, gp41 immunodominant region (IDR), KLIC, and
membrane proximal external region (MPER)) and aligned to gp160SHIV-1157ip (grey rows). Linear homologies are shaded grey. Numbers in parentheses
indicate how many times a given mimotope was selected independently. In a working definition, mimotopes were considered linear if they exhibited
more than 50% linear amino acid identity.
doi:10.1371/journal.pone.0003937.g001
HIV-C Mimotope Immuogens
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had induced maximal nAb responses or if a boost with native,
multimeric gp160 would be beneficial, we boosted 11 selected
mice (6 from the V3, 1 from the C-terminal, 2 from each, the IDR
and KLIC group) with gp160SHIV-1157ip and reassessed the
immune sera in comparison to those obtained after phage-boosts
only. Mean Env-ELISA titers were 1:1,220 after four phage boosts
compared to 1:2,748 after the additional gp160 boost, an increase
that did not reach statistical significance (p=0.1574; Figure S3A).
When tested for nAb responses against homologous SHIV-1157ip
or heterologous HIV-1SF162.LS, the additional Env boost did not
significantly raise nAb titers against either virus (p=0.8544 and
p=0.3935, respectively; Figure S3B), implying that maximal
responses had been induced by DNA prime/phage boosting.
Thus, the higher ELISA antibody titer after protein boosting did
not translate into better nAb titers.
Analysis of Vaccination-Induced Antibodies
Next, we sought to test whether antibodies induced by the
different immunogens reacted differently with native versus
denatured HIV-1 gp160. It is possible that the mixture of similar
but not identical mimotopes was able to broaden the immune
response and to induce antibodies against conformational epitopes
rather than linear ones. Our V3 mimotopes show incomplete
linear homology to gp160 and may contain structure-specific
homologies. In contrast, the gp120 C-terminal mimotopes are
linear.
We tested the post-protein boost sera (5
th bleed) for reactivity
against native and reduced HIV-1 gp160 by ELISA (Figure 8).
Two sera from mice boosted with V3-loop mimotopes showed
decreased binding upon denaturation of Env (7–14-fold). In
contrast, the signal obtained with serum from the mouse boosted
with mimotopes representing the HIV-1 gp120 C-terminus
Figure 2. Location of mimotope A12.2 on gp120. 3DEX analysis [52] was used to find structural homology between A12.2 (yellow, orange and
green) and the surface of gp120 (PDB ID: 2B4C) with the CD4 binding site shown in red and CCR5 coreceptor contact sites in blue. The inset table
shows partial V3 sequences for SHIV-1157ip, the protein structure used for the 3DEX analysis (2B4C), and A12.2. Amino acid residues resembling the
parental sequence but too few to form a linear epitope are shown in yellow and orange. Residues identified by 3DEX as showing 3D homology are
shown in green. All amino acids are in close proximity on the molecule’s surface and form a potential conformational mimotope of gp120 (Figure
prepared with Chimera [70]).
doi:10.1371/journal.pone.0003937.g002
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mimotopes induced conformational antibody responses, whereas
the gp120 C-terminal mimotopes induced predominantly linear
antibody responses.
Mimotope-induced antibodies against the gp41 IDR (Figure 8;
mouse #3.2) showed slightly increased binding upon denaturation
Figure 5. Reactivity profile of mimotope fusion proteins by
ELISA and Western blot. (A) Mimotope fusion proteins were tested
by ELISA with sera from monkeys RKl-8 and CF12. (B) Cross-reactivity of
mimotope fusion protein AIV12.4 (26 kD; arrowhead) with a panel of
rhesus monkey sera by Western blot. Two naı ¨ve sera (CF12, RJi-2) and a
fusion protein without mimotope insert (pPeptide) were used as
controls. Positive identification of the fusion proteins was via anti-His
tag antibody. Two human sera were used for additional testing: serum
from the infected source person harboring HIV-C, strain 1157iMVP41m,
and pooled sera from HIV-C-infected individuals.
doi:10.1371/journal.pone.0003937.g005
Figure 3. The conformational dependence of mimotope A12.2
by dot spot analysis with phage affinity-purified serum
antibodies. The following were spotted onto the filter: row A, native
gp160SHIV-1157ip; row B, denatured gp160SHIV-1157ip; row C, no protein
spotted; row D, anti-rhesus monkey IgG. In columns 1–4, rhesus
monkey antibodies affinity-purified with the following reagents were
applied: (1) recombinant phage A12.2 encoding mimotope identified as
conformational by 3DEX; (2) phage AIV12.4 encoding linear mimotope;
(3) WT phage; and (4) AIV12.4 incubated with naı ¨ve rhesus monkey
serum.
doi:10.1371/journal.pone.0003937.g003
Figure 4. Cross-reactivity of mimotope fusion proteins with
rhesus monkey sera showing broadly reactive nAbs. Mimotopes
were tested in the context of fusion proteins against 11 rhesus monkey
sera for binding reactivity by ELISA (see Figure S1). The binding pattern
is summarized using a color code for weak (orange), medium (blue) and
strong (red) binding.
doi:10.1371/journal.pone.0003937.g004
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immunized with the potentially conformational KLIC motifs
exhibited decreased binding after target denaturation (Figure 8),
implying that they are specific for conformational epitopes.
Anti-Mimotope Antibodies
To test if the last protein boost augmented the immune response
against the actual mimotopes, we cloned all V3 and C-terminal
mimotopes into expression vectors and generated fusion proteins
for ELISA analysis. Due to limited availability of mouse sera, we
selected one mouse from each group and tested the 4
th and 5
th
bleeds (#1.4 and #2.5) (Figure S3C, S3D). Interestingly, the
protein boost did not increase binding antibody titers against the
six mimotopes representing the V3 loop (Figure S3C). In contrast,
the HIV gp160 boost significantly increased the immune response
against the linear mimotopes from the C-terminal gp120 domain
by 6 to 9-fold (Figure S3D). This suggests that the conformational
V3-loop mimotopes induced structure-specific antibody responses
that were stimulated maximally by the one-time DNA priming
followed by recombinant phage boosting. As mentioned above, the
additional Env boost did not increase nAb titers.
These results support data presented in Figure 8 that mainly
linear epitopes were boosted by gp160, resulting in higher
binding antibody titers. However, gp160 boost-induced antibod-
ies did not significantly improve the neutralization capacity as
shown in Figure S3B. Potentially conformational anti-mimotope
responses (as represented by the V3 and KLIC groups) were not
boosted by the last protein boost (Figure S3C; data for KLIC not
shown). It seems our DNA prime/phage boost strategy did
achieve the maximum in nAb titers, although the binding titers
showed modest but insignificant increases after the last protein
boost.
Figure 6. Schedule for immunizations and blood collections in mouse study. After collecting the initial pre-bleeds, all mice were primed
with SHIV-1157ip env DNA (white triangle; Methods) followed by four phage boosts (grey triangles) every 4–5 weeks. Blood samples were collected
2–5 weeks after each boost (black/red/orange triangles). For a pilot test, 11 mice were selected to receive a final boost with trimeric gp160SHIV-1157ip
(green triangle).
doi:10.1371/journal.pone.0003937.g006
Figure 7. Analysis of post-phage boost (4
th bleed) mouse immune sera. (A) Anti-Env titers. Reciprocal serum dilution of each mouse for is
shown. (B) Neutralization. Bleeds were tested for 50% neutralization (IC50) against heterologous HIV-1SF162.LS.I C 50 values of each group are shown.
Groups represent mimotopes from the V3 loop (V3) and C-terminal domain of gp120 (C-terminal); immunodominant (IDR), KLIC, and membrane
proximal external region (MPER) of gp41. Red symbols indicate the use of the 3
rd bleed due to limited serum availability.
doi:10.1371/journal.pone.0003937.g007
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Here we have shown: 1) the isolation of mimotopes specific for
HIV-C Env, selected with serum from a clade C SHIV-infected
rhesus monkey with broadly reactive nAbs against different
clades of HIV; 2) using the 3D-structure of the clade B HIVJR-FL
in conjunction with 3DEX software analysis, we found Env
mimics that reflect structurally conserved elements and/or
conserved amino acid stretches, including motifs representing
V3 and the C-terminal domain of gp120, as well as the IDR, the
KLIC motif, and MPER of gp41; 3) 3DEX identified a
conformational V3 mimotope with only minimal linear sequence
homology. The conformational characteristics were confirmed
experimentally by differential recognition of native and dena-
tured Env using phage-affinity purified antibodies specific for
this V3 loop mimotope; 4) DNA priming with a HIV-C gp160-
encoding vector followed by repeated boosting with mimotope-
encoding phages induced antibodies in mice that specifically
bound to HIV gp160 and neutralized viruses with clade B and C
envelopes.
The key for a successful mimotope lies in the possibility of its
identification. Earlier attempts at identifying Env mimotopes only
had one tool available: sequencing of the peptide insert. An
important advance that finally allows identification based upon 3D
structure was the development of the 3DEX and similar software
[47,49,50,51,52]. We have given proof-of-concept for this new
approach with mimotope A12.2 and have brought the finding full-
circle by demonstrating differential recognition of native versus
denatured HIV-C gp160 by phage affinity-purified rhesus monkey
abs. Our data demonstrate that the use of random peptide phage
display to select disease-specific mimotopes from a large library in
combination with computational analysis may lead to the
identification of novel immunogens.
For one V3 mimotope (A12.2), we could show that gp160
conformation is important for binding of its cognate phage affinity-
purified antibody. The V3 loop is thought to adopt a highly
specific and conserved structure to mediate coreceptor interaction
[57,58]. Thus, even if variable in its sequence, the specificity of the
loop in its selective interaction may be a target for antibody-
mediated neutralization [59,60]. Our identified mimotopes may
represent conformational mimics of this loop and were able to
induce nAbs in mice.
Since biopanning using sera from other monkeys that also
exhibited broad neutralizing activity resulted in the isolation of
phage peptides similar to those selected with serum from animal
RKl-8, we tested their cross-recognition pattern by ELISA using
mimotope fusion proteins. Surprisingly, we did not see cross-
recognition of the conserved C-terminal domain mimotopes, but
several mimotopes of the V3 loop showed specific binding to
other monkey sera. Cross-recognition of epitopes or mimotopes
by various sera from HIV-infected individuals showing high
nAb-titers is frequently equated with its potential ability to
induce effective abs. Phage display with HIV-positive sera
primarily results in the identification of immunodominant
regions, such as KLIC, because of the abundance of antibodies
targeting this region [41]. However, the frequency with which an
epitope is recognized is not linked to neutralization and
mimotopes with no or limited cross-reactivity may be of interest
to nAb generation. The rhesus monkeys in our cohort may have
developed an unusually effective immune response against Env
in the context of natural infection, perhaps due to the fact that
our SHIV-C, SHIV-1157ip, encodes the env gene of a recently
transmitted virus. Interestingly, newly infected partners from a
cohort of HIV discordant couples not only harbored HIV-C
strains that were more easily neutralized than contemporaneous
virus from the infected source person, but the recently
transmitted HIV-C isolated also had shorter V-loops [61,62].
It is possible that Env molecules of recently transmitted HIV-C
have a more open configuration that favors the induction of
broadly reactive nAbs. The broad neutralization reactivity of our
rhesus monkey sera could be useful in identifying non-
immunodominant but structurally conserved domains. Even
though in the context of a natural infection this may be a rare
response and not occur in each host, it could potentially be
induced with epitope mimics which focus the immune response
only to the part linked to nAbs.
Previous studies have shown that whole phage particles can be
used to induce peptide-specific antibodies and protective immune
responses in animals [37,63,64]. Our immunization with mimo-
tope mixtures differs in a significant way from these earlier studies,
which showed limited efficacy. Instead of using a series of multiple
immunizations with recombinant phages expressing mimotopes as
used by this group, we employed a novel DNA prime/
recombinant phage boost strategy. We chose to use only a single
priming with a DNA vector encoding the entire gp160, which will
not generate binding or nAb responses [56]; we reasoned that a
single DNA priming would imprint the immune system with the
correct image of native gp160 structures, without diverting ab
responses to immunodominant but ultimately unimportant Env
regions. Instead, we hypothesized that our boosting with
mimotopes would allow us to manipulate humoral immune
responses by focusing them on important structural domains.
This promising immunofocusing approach was shown to be
effective in eliciting anti-Env abs. The immunization regimen
consists of immunogens which focus the immune response on one
or a few neutralizing epitopes. This potentially results in a larger
proportion and higher titer of nAbs. Even though the use of
selected epitopes or mimotopes as vaccines to focus the immune
response on neutralizing domains is still in its beginning, several
examples in the last years show the successful induction of nAbs
against V2 and/or V3 [65,66,67]. We chose to perform the boosts
with five different mimotope groups, each representing a well-
defined Env region (the V3 loop, the C-terminus of gp120, gp41
Figure 8. Reducing Env ELISA. Mouse immune sera were tested for
binding to native (blue/orange bars) and reduced Env (black bars).
Three mice were immunized with potential conformational mimotopes
(#1.2, 1.4 and 4.2; blue), two mice with linear mimotopes (#2.5 and 3.2;
orange).
doi:10.1371/journal.pone.0003937.g008
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our reductionist’s approach would give us a chance to identify
novel HIV Env regions capable of inducing nAbs in the absence of
the otherwise overpowering influence of immunodominant
regions. Indeed, this strategy was successful: for the first time,
the C-terminal domain of gp120, previously identified as
immunogenic but never linked to nAb responses [68,69], was
shown to induce nAbs. Interestingly, our DNA prime/phage
mimotope boosts strategy appeared to have induced the maximal
nAb responsiveness to a given domain, since additional boosting
with the native, multimeric gp160 failed to significantly raise the
nAb titers.
Our results show that the combination of phage display and
3DEX analysis is a powerful tool to analyze the humoral immune
response by identifying novel antigenic mimics that represent
functionally conserved Env domains, such as V3 or the C-terminal
domain of gp120. Using an innovative DNA prime/phage boost
regimen, we induced cross-clade nAbs against HIV clades B and C
and for the first time, linked the C-terminal domain of gp120 to
antibody-mediated neutralization in mice.
Materials and Methods
Animals
Indian-origin rhesus monkeys (Macaca mulatta) were housed at
the Yerkes National Primate Research Center (YNPRC), Atlanta,
Georgia, USA, a facility fully accredited by the Association for
Assessment and Accreditation of Laboratory Animal Care
International (AAALAC). All procedures were approved by the
Animal Care and Use Committees of Emory University and the
Dana-Farber Cancer Institute.
Female BALB/c mice (Mus musculus) were purchased from
Taconic Farms (Germantown, NY) and enrolled in the study at 6–
8 weeks of age and housed at the Harvard School of Public
Health, Boston, Massachusetts, USA, a facility fully accredited by
the Association for Assessment and Accreditation of Laboratory
Animal Care International (AAALAC). All procedures were
performed in accordance with the guidelines of the Animal Care
and Use Committees of Harvard Medical School and the Dana-
Farber Cancer Institute.
Monkey serum
Serum for this study was collected from rhesus monkey RKl-8,
an animal described earlier [33]. Briefly, this monkey was
infected with a pathogenic R5 SHIV, termed SHIV-1157ip,
which encodes the env gene of HIV-C, the most prevalent HIV-1
subtype worldwide. Approximately 10% of the rhesus monkeys
infected with SHIV-1157ip or the related SHIV-1157ipd3N4
developed high-titer, broadly reactive nAbs not only against
homologous SHIV-1157ip and the corresponding primary HIV-
C, but also against heterologous strains of HIV-1 clades B and C
(Table 1). These monkeys had been used in various experiments
(rapid animal-to-animal passage to adapt the parental construct
to rhesus monkeys, viral titrations, and vaccine challenge
studies)[55].
Phage display biopanning
Paramagnetic beads (Dynabeads M-280 tosyl activated; Invitro-
gen, Carlsbad CA, USA) were coated with a rabbit anti-monkey
IgG (Sigma-Aldrich, St. Louis MO, USA) according to the
manufacturer’s instructions. Coated beads were pre-incubated
while rotating for 2 h at room temperature with rhesus monkey
serum (1:250 in phosphate buffered saline/0.25% gelatin, PBSG;
Gibco-Invitrogen, Grand Island NY, USA; Fisher Scientific, Fair
Lawn NJ, USA). Beads were washed 56with PBSG/0.5% (w/v)
Tween-20 (PBSGT; Sigma-Aldrich) and then incubated while
rotating overnight at 4uC with 10 ml of the original phage-
displayed peptide library (New England Biolabs, Ipswich MA,
USA). Biopannings of all three libraries (7mer, cyclic 7mer and
12mer) were performed in parallel using separate tubes. The next
day, beads were washed 106with 1 ml PBSGT and bound phages
were eluted by pH shift with 0.2 M glycine-HCl pH 2.2
supplemented with 1 mg/ml BSA (Sigma-Aldrich). After neutral-
ization with 1 M Tris-HCl pH 9.1 (Sigma-Aldrich), eluted phages
were subjected to negative selection as described above using
pooled sera from non-infected control monkeys. Phages remaining
from the negative selections were amplified in Escherichia coli
(ER2738, New England Biolabs), precipitated overnight at 4uC
(20% PEG-8000/2.5 M NaCl; Fisher Scientific) and used for a
second and third round of selection. After the third positive
selection, the phages were titered, and single clones were picked
and tested by phage ELISA for specific binding. Positives clones
were amplified and sequenced to deduce their peptide insert.
Phage ELISA
Plates (Greiner-Bio-One GmbH, Frickenhausen, Germany)
were coated overnight at 4uC with 100 ml/well serum (1:5,000
in carbonate-bicarbonate buffer; Sigma-Aldrich). The next day,
plates were blocked (1 h, room temperature) with 200 ml/well 3%
casein (Sigma-Aldrich) in PBS/0.5% Tween-20 (PBSCT) and
washed 36 with 300 mld H 2O in an automated plate washer
(BioTek Instruments, Inc., Winooski VT, USA). Then, 70 mlo f
control or positively selected phages that had been amplified
overnight were added to 30 ml PBSCT and incubated overnight at
4uC. Plates were washed 36 and incubated for 1 h at RT with
100 ml/well of an anti-phage horse-radish peroxidase (HRP)-
conjugated antibody (1:2,000 in PBSCT; GE Healthcare Bio-
Sciences Corp., Piscataway NJ, USA). After washing 56, the
plates were developed with 100 ml/well o-phenylenediamine in
phosphate-citrate buffer (Sigma-Aldrich), stopped with 100 ml/
well 1 N H2SO4 (VWR, West Chester PA, USA) and read at 490/
620 nm.
Mimotope analysis
Phage insert sequences were analyzed using the computer
program 3DEX [52]. After checking for linear homology to
SHIV-1157ip gp160 [33], the peptide sequences were compared
to published PDB structure files of HIV-1 gp120 [32,53] to
identify conformational homology. Phages were grouped accord-
ing to their peptide motifs, and selected phages were used for
further analysis and immunization studies.
Immunization of mice
Selected recombinant phages were grouped according to motifs;
each group consisted of 5–6 phages with similar but not identical
peptide sequences. Phages of each group were combined and used
as five different mixtures for immunization. Mice were primed
once with SHIV-1157ip env DNA (intramuscularly; 100 mgi n
100 ml PBS) and boosted subcutaneously (s.c.) with 10
12 phage
particles in 100 ml PBS/MPL (Sigma-Aldrich) every 4–5 weeks.
Serum samples were collected 2–5 weeks after each boost. After
four phage boosts, serum samples were tested for their neutralizing
capacity against HIV-1SF162.LS and SHIV-1157ip. In a pilot study,
11 mice were given an additional boost with trimeric SHIV-
1157ip gp160 (s.c.; 20 mg in 100 ml PBS with incomplete Freund’s
adjuvant (IFA) (Sigma-Aldrich) and their sera were tested for the
presence of neutralizing antibodies.
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SHIV-1175ip was prepared in rhesus monkey PBMC, HIV
pIndieC was prepared in human PBMC and HIVSF162.LS
pseudovirus (kindly provided by David Montefiori) was prepared
using cotransfection of 293T cells with an env expression plasmid
and Denv backbone vector. TZM-bl cells encode the luciferase
gene under the control of the HIV-1 promoter; both CD4 and
CCR5 are also expressed on the cell surface (AIDS Research and
Reference Program, Division of AIDS, NIAID, NIH). A total of
5,000 cells/well were seeded overnight in 100 ml DMEM/10%
FCS (Gibco-Invitrogen, Grand Island NY, USA). Serial 2-fold
dilutions of immune sera were prepared in triplicates in 96-well
round-bottom plates (Becton Dickenson, Franklin Lakes NJ, USA).
In parallel, the pre-immune sera were serially diluted and used as
controls. ‘‘Virus only’’ wells received 50 ml medium. The virus was
diluted (1:500 for SHIV-1157ip: 36 ng/ml p27; 1:500 for HIV
pIndieC: 35 ng/ml p24; 1:300 for HIVSF162.LS: 300 ng/mlp24) and
50 ml of virus was added to all wells. The plate was incubated for 1 h
at 37uCi n5 %C O 2, after which time 10 mlo fa4 0 0mg/ml DEAE-
Dextran solution (Sigma-Aldrich) was added to all wells and the
entiremixturewastransferredintothe96-wellflat–bottomplatewith
the seeded TZM-bl cells. The next day, medium was replaced with
fresh medium and incubated another 24 h. Bright-Glo luciferase
substrate (Promega, Madison WI, USA) was added to the plate the
following day and luciferase activity was measured. The percent
neutralization was calculated using the following equation:
%Neutralization~ 1{
Luciferase immune serum
Luciferase pre{immune serum
 
 100
Dot spot analysis
Trimeric SHIV-1157ip gp160 was spotted onto a nitrocellulose
membrane (Whatman GmbH, Dassel, Germany) (50 ng/spot in
native or reduced conditions (10 mM TCEP (Pierce, Rockford IL,
USA); 1% SDS (Sigma-Aldrich); boiled for 2 min). Strips were
blocked with PBSCT for 1 h at room temperature and incubated
overnight at 4uC with antibodies (diluted in PBSCT). The next
day, strips were washed 36with PBST and incubated with anti-
monkey IgG HRP-conjugate (1:2,000 in PBSCT; Sigma-Aldrich).
After 1 h at room temperature, strips were washed 56with PBST
and developed using Opti-4CN substrate (Bio-Rad Laboratories,
Hercules CA, USA).
ELISA
Plates were coated overnight at 4uC with 100 ng/well native or
reduced (10 mM TCEP/1% SDS; boiled for 2 min) proteins in
100 ml coating buffer. After washing 36, plates were blocked with
200 ml/well PBSCT for 1 h at room temperature and then
incubated overnight at 4uC with mouse serum (1:175) or rhesus
monkey serum (1:800; 100 ml/well diluted in PBSCT). Plates were
washed 36 and incubated with HRP-conjugated antibodies
(1:2,000 in PBSCT, 100 ml/well) for 1 h at room temperature.
After washing 56, plates were developed using 100 ml/well o-
phenylenediamine in phosphate-citrate buffer, stopped with
100 ml/well 1 N H2SO4 and read at 490/620 nm.
Mimotope fusion proteins
Fusion proteins were cloned into the expression vector
pPEPTIDE according to manufacturer’s instructions (MoBiTec
GmbH, Go ¨ttingen, Germany). Briefly, phage peptide insert
were amplified using two primers (pPeptide-rev: 59-GGCC
CGGGGATCCTAACTTTCAACAGTTTCGGCCGAACCTC
CACC; pPeptide-fw: 59-CGCCCGCGGATTAATGGCCCTT-
TAGTGGTACCTTTCTATTCTCACTCT) to introduce the
underlined cloning restriction sites, digested with AseI and BamHI
(Fermentas Inc., Glen Burnie MD, USA) and gel-purified using
NucleoSpin Extract II (Macherey-Nagel Inc., Bethlehem PA,
USA). Six ng of mimotope DNA were ligated with 100 ng vector
and transformed into BL21(DE3) cells (Novagen, Madison WI,
USA). After sequence analysis, proteins were expressed according
to the manual and purified using standard chromatography using
the Ni-charged Profinity IMAC resin (Bio-Rad). Of note, the
vector encodes a His tag to assess fusion protein expression. The
plasmid is based on the pET expression vector system and
induction of the T7 promoter leads to the expression of a highly
expressed fusion protein (89 aa) followed by a higher affinity
poly(His) region (53 aa) for purification and the C-terminal
mimotope. The expressed mimotope fusion protein migrates at a
size of around 26 kD.
Western blot
Standard SDS PAGE was performed with 40 mg protein per gel
(Bio-Rad). Protein was transferred onto a nitrocellulose membrane
(Bio-Rad) using a wet blot apparatus (Bio-Rad). The membrane
was cut into strips, blocked with 3% PBSCT and individual strips
were incubated with the appropriate serum (1:200) or antibodies
(1:1,000 in 3% PBSCT) overnight at 4uC. Membranes were
washed 36 and incubated for 1 h at room temperature with an
HRP-conjugated antibody (1:2,000 in 3% PBSCT). After washing
56, the strips were developed with Opti-4CN substrate (Bio-Rad).
Statistical analysis
Statistics were calculated using a two-tailed paired t test and
only applied to matching pairs of mice comparing the significance
between the post-phage boosts and post-gp160 boost (GraphPad
Prism 5 for Windows, GraphPad Software).
Supporting Information
Figure S1 Cross-reactivity profile of mimotope fusion proteins
by ELISA. Mimotope fusion proteins were tested by ELISA for
cross-recognition with 9 SHIV-positive monkey sera from our
cohort. Two naı ¨ve sera (CF12, RJi-2) and a fusion protein without
mimotope insert (pPeptide) were used as negative controls.
Found at: doi:10.1371/journal.pone.0003937.s001 (0.94 MB
DOC)
Figure S2 Serum reactivity with AIV12.4. The linear mimotope
fusion protein AIV12.4 was tested for reactivity with various RKl-
8 sera by ELISA. As negative controls, two naı ¨ve RM sera (CF12,
RJi-2) were included.
Found at: doi:10.1371/journal.pone.0003937.s002 (1.30 MB
DOC)
Figure S3 Analysis of immune mouse sera after DNA prime/
phage boosting or DNA prime/phage+gp160 boosting. (A) Anti-
Env titers. Reciprocal serum dilution of each mouse for the post-
phage boosts and post-gp160 boost is shown. Red symbols indicate
3rd vs. 5th bleed, green symbol indicates no matching 5th bleed,
both due to serum restrictions. (B) Neutralization with mouse
immune sera. Bleeds were tested for 50% neutralization (IC50)
against homologous SHIV-1157ip and heterologous HIV-
1SF162.LS. Post-phage boosts (triangles) are compared to post-
gp160 boost (squares). (C, D) Vaccination-induced antibody
responses against conformational and linear mimotopes. Mimo-
topes were cloned and expressed as fusion proteins. The latter
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or DNA priming/phage+gp160 boosting (squares) of mice had
induced antibodies against the original phage-encoded peptide
mimotopes. Sera from two selected mice were tested for reactivity
to each of the mimotopes used in the immunization mixture. (C)
Mouse #1.4, immunized with potential conformational V3-loop
mimotopes. (D) Mouse #2.5, immunized with linear C-terminal
mimotopes.
Found at: doi:10.1371/journal.pone.0003937.s003 (0.91 MB
DOC)
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